利福平耐药耐甲氧西林金黄色葡萄球菌菌血症的临床与微生物学特征
韩国某三级医院2007年3月至2020年5月961例MRSA菌血症成人患者中,61例(6.3%)为利福平耐药分离株感染。利福平耐药组90天复发率高于敏感组(18.0% vs 6.2%,P < 0.001),调整混杂因素后利福平耐药与90天复发显著相关(subdistributional HR 2.31;95% CI 1.05-5.10;P = 0.04),两组90天死亡率无显著差异(27.9% vs 29.2%,P = 0.94)。
要点
- 961例MRSA菌血症中61例(6.3%)为利福平耐药分离株感染。
- 利福平耐药组90天复发率18.0% vs 敏感组6.2%(P < 0.001)。
- 调整后利福平耐药与90天复发独立相关(subdistributional HR 2.31;95% CI 1.05-5.10;P = 0.04)。
核心结论
- 利福平耐药MRSA分离株在多重耐药和高万古霉素MIC方面表现出独特的微生物学特征。
- 尽管两组MRSA菌血症管理无显著差异,利福平耐药组复发显著更常见。
- 利福平耐药可能在感染复发中起重要作用。
研究设计与样本
- 数据收集自2007年3月至2020年5月在韩国某三级医院住院的MRSA菌血症成人患者。
- 比较利福平耐药MRSA感染患者与利福平敏感分离株感染患者的临床特征和治疗结局。
- 评估90天全因死亡和MRSA感染复发。
主要发现
- 961例MRSA菌血症患者中61例(6.3%)为利福平耐药分离株感染。
- 两组感染灶类型和菌血症持续时间无显著差异。
- 利福平耐药MRSA分离株更可能有多重耐药和更高的万古霉素MIC。
- 利福平耐药组90天复发率高于敏感组(18.0% vs 6.2%,P < 0.001),两组90天死亡率无显著差异(27.9% vs 29.2%,P = 0.94)。
- 调整潜在混杂因素后,利福平耐药与90天复发显著相关(subdistributional HR 2.31;95% CI 1.05-5.10;P = 0.04)。
关键数值与推荐
- 利福平耐药组90天复发率18.0% vs 利福平敏感组6.2%(P < 0.001)。
- 利福平耐药组90天死亡率27.9% vs 利福平敏感组29.2%(P = 0.94)。
- 调整后利福平耐药与90天复发的subdistributional HR 2.31(95% CI 1.05-5.10;P = 0.04)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The clinical significance of rifampicin resistance in Staphylococcus aureus infections has not been demonstrated. Here, we evaluated the clinical characteristics of rifampicin-resistant S. aureus infection. METHODS: Data were collected from adult patients who were hospitalized with MRSA bacteraemia between March 2007 and May 2020 at a tertiary hospital in South Korea. The clinical characteristics and treatment outcomes of patients infected with rifampicin-resistant MRSA were compared with those of rifampicin-susceptible isolates. All-cause death and recurrence of MRSA infection were assessed for 90 days. RESULTS: Of the 961 patients with MRSA bacteraemia, 61 (6.3%) were infected by rifampicin-resistant isolates. The type of infection focus and duration of bacteraemia did not significantly differ between the two groups. Rifampicin-resistant MRSA isolates were more likely to have multidrug resistance and a higher vancomycin MIC relative to the rifampicin-susceptible isolates. The 90-day recurrence rate was higher in the patients infected with rifampicin-resistant MRSA compared with those with rifampicin-susceptible MRSA (18.0% versus 6.2%, P < 0.001), whereas the 90-day mortality was comparable between the two groups (27.9% versus 29.2%, P = 0.94). After adjusting for potential confounding factors, rifampicin resistance was significantly associated with 90-day recurrence (subdistributional HR: 2.31; 95% CI: 1.05-5.10; P = 0.04). CONCLUSIONS: Rifampicin-resistant MRSA isolates showed distinct microbiological features in terms of multidrug resistance and a high vancomycin MIC. Although the management of MRSA bacteraemia was not significantly different between the two groups, recurrence was significantly more common in the rifampicin-resistant group. Rifampicin resistance may play a significant role in infection recurrence.
引用
- Bae S, Kim ES, Lee YW, et al. Clinical and microbiological characteristics of rifampicin-resistant MRSA bacteraemia. J Antimicrob Chemother. 2023. PMID: 36537200. doi:10.1093/jac/dkac428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。